Immuneering Corp Cl A (IMRX) Stock Price, Quote & News

Company Profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inh...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8080

Website: immuneering.com

Address:

245 Main Street, Second Floor, Cambridge, United States

prevclose Sep. 12 at 4:19 AM

$IMRX Chat is valuing this based on probablitues of success. It gives IMRX a 60% probability of success and $150M failure value: (60% × $1.5B) + (40% × $150M) = $960M Divided by 75M diluted shares = approximately $12.80/share. I'll take thst for mow.

1 · Reply

Captenotwo Sep. 11 at 7:40 PM

$IMRX for what it’s worth I bought a little more at $4.27 Cheers Cap

0 · Reply

D541 Sep. 11 at 7:12 PM

$IMRX someone must know that you're such a clown, the entire biotech is down 20%...wake up pal!!!

0 · Reply

Eruption Sep. 11 at 7:04 PM

$IMRX Down & down & down she goes. Wonderful. To the monsters who do this, I hope you will need this drug one day, bastards.

0 · Reply

rekc Sep. 11 at 6:33 PM

$IMRX it appears someone knows that the trials are not going well.

1 · Reply

bullwink Sep. 11 at 4:45 PM

$IMRX Nearing 52 week low. What a waste for shareholders. Like I said great science but ZERO confidence by WS in this management. Hope to see at least patients benefit from this.

1 · Reply

Eruption Sep. 11 at 3:47 PM

$IMRX 5% drop for absolutely no reason other than manipulators doing their evil deeds. Nice.

0 · Reply

prevclose Sep. 11 at 3:02 PM

$IMRX Chat says there is 55 to 65 percent chance phase 3 will be a success. Gives it a forecasts around $12.

1 · Reply

ZacksResearch Sep. 11 at 1:20 PM

🧬 A key $IMRX catalyst is coming into view Immuneering is set to present new atebimetinib data at the upcoming AACR Conference on Pancreatic Cancer, highlighting how the drug's dual mechanism could support longer survival. Why it matters: • The presentation will expand on prior data showing 84% of evaluable first-line pancreatic cancer patients maintained or gained weight at three months • New analyses will examine how tumor-volume reduction and preservation of body mass may each contribute to overall survival • Atebimetinib is already being evaluated in the pivotal Phase 3 MAPKeeper 301 study • The AACR presentation is scheduled for Sept. 26, putting fresh clinical data in focus later this month Price target breakdown here 👇 https://www.zacks.com/stock/research/IMRX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-39540&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_39540

1 · Reply

Eruption Sep. 10 at 7:37 PM

$IMRX Nothing new in that discussion. What will it take to move the needle on this stock? Last Sep 24, up to $10. Dropped ne,t day and ever since, staying in this dead zone of $4.50 to $6. How could a drug eith such hood resilts so far be SO far below its competitor? Makes no sense.

1 · Reply

Immuneering Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2026, 7:30 AM EDT - 3 days ago

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival

Sep 3, 2026, 4:05 PM EDT - 9 days ago

Immuneering to Participate in Upcoming Investor Conferences

2026-08-26T21:20:30.000Z - 17 days ago

Immuneering says FDA approval of pancreatic cancer treatment ‘good news’

Aug 26, 2026, 5:16 PM EDT - 17 days ago

Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

2026-08-06T10:11:45.000Z - 5 weeks ago

Immuneering initiated with a Buy at H.C. Wainwright

Aug 5, 2026, 7:30 AM EDT - 5 weeks ago

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aug 5, 2026, 7:30 AM EDT - 5 weeks ago

Immuneering Earnings release: Q2 2026

Aug 5, 2026, 7:30 AM EDT - 5 weeks ago

Immuneering Quarterly report: Q2 2026

2026-07-21T21:10:16.000Z - 7 weeks ago

Immuneering publishes preclinical data on atebimetinib in Cancer Research

Jul 21, 2026, 4:05 PM EDT - 7 weeks ago

Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

Jul 17, 2026, 4:05 PM EDT - 1 month ago

Immuneering Corporation Announces Grants of Inducement Awards

2026-07-08T11:50:16.000Z - 2 months ago

Immuneering initiated with an Overweight at Cantor Fitzgerald

2026-06-15T11:43:43.000Z - 3 months ago

Immuneering appoints Andrew Gengos as CFO

Jun 15, 2026, 7:30 AM EDT - 3 months ago

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Jun 11, 2026, 11:00 AM EDT - 3 months ago

Immuneering Transcript: AGM 2026

Jun 11, 2026, 7:30 AM EDT - 3 months ago

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

2026-06-01T13:26:29.000Z - 3 months ago

Immuneering announces updated clinical data from atebimetinib combination trial

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Immuneering Transcript: Study result

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Immuneering Press release: Study result

Jun 1, 2026, 7:30 AM EDT - 3 months ago

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

May 21, 2026, 5:00 PM EDT - 3 months ago

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

2026-05-15T14:03:04.000Z - 4 months ago

Immuneering reports Q1 EPS (21c), consensus (25c)

May 15, 2026, 7:35 AM EDT - 4 months ago

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026, 7:30 AM EDT - 4 months ago

Immuneering Earnings release: Q1 2026

May 15, 2026, 7:30 AM EDT - 4 months ago

Immuneering Quarterly report: Q1 2026

2026-04-21T21:01:42.000Z - 4 months ago

Immuneering announces updated data from Phase 2a trial for atebimetinib

Apr 21, 2026, 4:05 PM EDT - 4 months ago

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

2026-04-20T14:04:20.000Z - 4 months ago

Immuneering announces presentation of new genetic data at 2026 AACR

Apr 20, 2026, 9:00 AM EDT - 4 months ago

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Immuneering Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Immuneering Proxy statement: Proxy filing

Apr 13, 2026, 3:45 PM EDT - 5 months ago

Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 4:05 PM EDT - 5 months ago

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 17, 2026, 4:35 PM EDT - 5 months ago

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Mar 9, 2026, 3:40 PM EDT - 6 months ago

Immuneering Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T10:56:34.000Z - 6 months ago

Immuneering price target lowered to $12 from $13 at Piper Sandler

Mar 6, 2026, 8:00 AM EST - 6 months ago

Immuneering Annual report: Q4 2025

Mar 6, 2026, 8:00 AM EST - 6 months ago

Immuneering Earnings release: Q4 2025

2026-03-06T12:52:29.000Z - 6 months ago

Immuneering reports Q4 EPS (18), consensus (31c)

2026-03-06T12:52:10.000Z - 6 months ago

Immuneering sees cash runway into 2029

Mar 6, 2026, 7:45 AM EST - 6 months ago

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 2, 2026, 4:05 PM EST - 6 months ago

Immuneering to Present at the Leerink Global Healthcare Conference

Feb 26, 2026, 10:00 AM EST - 6 months ago

Immuneering Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 4:05 PM EST - 6 months ago

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-08T17:55:15.000Z - 8 months ago

Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink

RVMD

Jan 7, 2026, 4:30 PM EST - 8 months ago

Immuneering Transcript: Study Result

Jan 7, 2026, 4:30 PM EST - 8 months ago

Immuneering Press release: Study Result

Jan 7, 2026, 4:00 PM EST - 8 months ago

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Dec 23, 2025, 8:00 AM EST - 8 months ago

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Dec 17, 2025, 4:05 PM EST - 8 months ago

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Dec 16, 2025, 8:00 AM EST - 9 months ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 4, 2025, 11:10 AM EST - 9 months ago

Immuneering Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 9 months ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 4:30 PM EST - 10 months ago

Immuneering Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Immuneering Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Immuneering Earnings release: Q3 2025

Nov 12, 2025, 4:05 PM EST - 10 months ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 4, 2025, 4:05 PM EST - 10 months ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Sep 26, 2025, 4:01 PM EDT - 11 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 25, 2025, 12:08 AM EDT - 11 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 11 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:01 PM EDT - 11 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 16, 2025, 7:00 AM EDT - 12 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Immuneering Registration statement: Registration Filing

Aug 26, 2025, 4:05 PM EDT - 1 year ago

Immuneering Announces Closing of $25 Million Private Placement

Aug 25, 2025, 8:00 AM EDT - 1 year ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Aug 21, 2025, 8:00 AM EDT - 1 year ago

Immuneering Announces $25 Million Private Placement

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Immuneering Registration statement: Registration Filing

Aug 13, 2025, 12:00 AM EDT - 1 year ago

Immuneering Quarterly report: Q2 2025

Aug 13, 2025, 12:00 AM EDT - 1 year ago

Immuneering Earnings release: Q2 2025

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Transcript: Study Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Press release: Study Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Slides: Study Update

Jun 17, 2025, 6:00 AM EDT - 1 year ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Immuneering Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 12:00 AM EDT - 1 year ago

Immuneering Quarterly report: Q1 2025

May 5, 2025, 12:00 AM EDT - 1 year ago

Immuneering Earnings release: Q1 2025

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immuneering Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immuneering Proxy statement: Proxy Filing

Apr 9, 2025, 1:30 PM EDT - 1 year ago

Immuneering Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Immuneering Corporation Announces Grant of Inducement Award

Mar 20, 2025, 5:00 PM EDT - 1 year ago

Immuneering Annual report: Q4 2024

Mar 20, 2025, 5:00 PM EDT - 1 year ago

Immuneering Earnings release: Q4 2024

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Feb 12, 2025, 2:40 PM EST - 1 year ago

Immuneering Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 3, 2025, 4:05 PM EST - 1 year ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Transcript: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Press release: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Slides: Study Result

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 5, 2024, 1:00 PM EST - 1 year ago

Immuneering Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immuneering Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immuneering Earnings release: Q3 2024

Sep 12, 2024, 4:30 PM EDT - 2 years ago

Immuneering Transcript: Study Update

Sep 12, 2024, 4:30 PM EDT - 2 years ago

Immuneering Press release: Study Update

Sep 12, 2024, 4:05 PM EDT - 2 years ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

prevclose Sep. 12 at 4:19 AM

1 · Reply

Captenotwo Sep. 11 at 7:40 PM

$IMRX for what it’s worth I bought a little more at $4.27 Cheers Cap

0 · Reply

D541 Sep. 11 at 7:12 PM

$IMRX someone must know that you're such a clown, the entire biotech is down 20%...wake up pal!!!

0 · Reply

Eruption Sep. 11 at 7:04 PM

$IMRX Down & down & down she goes. Wonderful. To the monsters who do this, I hope you will need this drug one day, bastards.

0 · Reply

rekc Sep. 11 at 6:33 PM

$IMRX it appears someone knows that the trials are not going well.

1 · Reply

bullwink Sep. 11 at 4:45 PM

$IMRX Nearing 52 week low. What a waste for shareholders. Like I said great science but ZERO confidence by WS in this management. Hope to see at least patients benefit from this.

1 · Reply

Eruption Sep. 11 at 3:47 PM

$IMRX 5% drop for absolutely no reason other than manipulators doing their evil deeds. Nice.

0 · Reply

prevclose Sep. 11 at 3:02 PM

$IMRX Chat says there is 55 to 65 percent chance phase 3 will be a success. Gives it a forecasts around $12.

1 · Reply

ZacksResearch Sep. 11 at 1:20 PM

1 · Reply

Eruption Sep. 10 at 7:37 PM

1 · Reply

Merlintrader Sep. 10 at 6:22 PM

Elaborato per 11s Immuneering ($IMRX): September 26 AACR Poster to Examine Tumor Shrinkage, Body Mass and Survival with Atebimetinib — Updated Sep 10 https://www.merlintrader.com/immuneering-corporation-stock-hub/

0 · Reply

rickahuna Sep. 10 at 1:42 PM

$IMRX Immuneering to Present Data on Atebimetinib’s Tumor-Reducing and Body Mass-Preserving Effects in Pancreatic Cancer at AACR Conference Posted: an hour ago / Sept. 10, 2026 11:41 a.m. UTC

0 · Reply

LagerHound Sep. 9 at 7:56 PM

$IMRX

0 · Reply

Cheesyisi Sep. 7 at 4:10 PM

$IMRX

0 · Reply

ItsaGameChanger Sep. 7 at 1:40 PM

$IMRX Latest Report 09/04/2026 LSEG maintains a current price target of $17.17 for IMRX

0 · Reply

Merlintrader Sep. 7 at 6:33 AM

Immuneering ($IMRX): What Comes Next for MAPKeeper Across 43 Sites? Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/immuneering-corporation-stock-hub/

0 · Reply

OptimistJP Sep. 3 at 9:17 PM

$IMRX https://ir.immuneering.com/news-releases/news-release-details/immuneering-participate-upcoming-investor-conferences

0 · Reply

combat_cannabis Sep. 2 at 7:46 PM

$IMRX the close today changes everything. Reclaiming 5$ and overtaking the past 2 days of red dailies

1 · Reply

JuggernautRaider Sep. 2 at 2:51 PM

$IMRX 🤤

0 · Reply

bullwink Sep. 2 at 11:54 AM

$IMRX There is a complete lack of trust for IMRX management on WS. The CEO does not seem to be well recognized and respected in biotech world although he has done excellent job in getting drug to Ph3 There is no way a Phase 3 Pancreatic cancer biotechs with promising 1L Phase 2 data that is equivalent to $RVMD 2L data or even better in terms of toxicity trades under 300 million valuation. Replace the management (especially CEO) with a high profile CEO and you will see stock double or triple in matter of days.

1 · Reply

JuggernautRaider Sep. 1 at 11:22 AM

$TNXP $IMRX $CCCC $ALT Hey America can you come get this guy? He is clearly on something. Why are Christians so dramatic as Marcus Aurelius called us in “Meditations”? Hmm 🧐 https://www.linkedin.com/pulse/why-ohio-friday-night-lights-have-never-been-beaten-ask-jeff-conroy-tkmse

1 · Reply

JuggernautRaider Aug. 31 at 9:49 PM

$TNXP $TLSA $IMRX $ALT 💊 🧠 🍱 🧬 🧘‍♂️

0 · Reply

Market Cap	276.26M
Revenue (ttm)	0.00
Net Income (ttm)	-56.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	911,000
Avg Vol	746,746
Day's Range	N/A - N/A
Shares Out	64.70M
Stochastic %K	3%
Beta	0.40
Analysts	Strong Sell
Price Target	$17.50